Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

fludarabine 3Vaccines 3Radiotherapy 3Papillomavirus Vaccines 3Nivolumab 3Cyclophosphamide 3pembrolizumab 2entinostat 2aldesleukin 2aflibercept 2Trastuzumab 2Surveys and Questionnaires 2Specimen Handling 2Radiation 2Observation 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2Adoptive Transfer 2trastuzumab deruxtecan 1tivozanib 1tipifarnib 1rocakinogene sifuplasmid 1oncogene protein E7, Human papillomavirus type 16 1nanocis 1durvalumab 1bintrafusp alfa protein, human 1atezolizumab 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × MEDI0457 × Gastrointestinal × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡